Alzheimer’s disease can feel like a thief, sneaking in to steal memories, independence, and the moments that matter most. ...

Merging biophysics with knowledge of how the brain handles waste led to an impressive 50 percent reduction of amyloid beta in ...

Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer's Detection ...

Historically, we have relied on endomyocardial biopsy for the confirmation of the diagnosis for transthyretin cardiac ...

But while lecanemab has been shown to slow the progression of disease in some people who receive an early diagnosis, it comes ...

Painless brain imaging can map elevated pulsation of microvessels, which is potentially connected to memory loss and Alzheimer's risk.

European Commission grants marketing authorization to Lilly's Kisunla to treat early symptomatic Alzheimer's disease: Indianapolis Saturday, September 27, 2025, 09:00 Hrs [IST] El ...

Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ...

Algernon Pharmaceuticals Inc. (the 'Company” or 'Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it has signed a definitive equipment order and ...

Over time, transthyretin amyloidosis (ATTR) can damage the nerves, heart, and other organs. This may lead to complications like heart problems, nerve damage, and trouble with everyday bodily functions ...

CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...